Lupin receives $50 million from Boehringer Ingelheim for achievement of key milestones

In 2019, Lupin and Boehringer Ingelheim had inked a licensing, development and commercialisation agreement for Lupin’s novel oncology compound.In 2019, Lupin and Boehringer Ingelheim had inked a licensing, development and commercialisation agreement for Lupin’s novel oncology compound.Read More